Publications Research group Plank

1. Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA.
Schrom E, Huber M, Aneja M, Dohmen C, Emrich D, Geiger J, Hasenpusch G, Herrmann-Janson A, Kretzschmann V, Mykhailyk O, Pasewald T, Oak P, Hilgendorff A, Wohlleber D, Hoymann HG, Schaudien D, Plank C, Rudolph C, Kubisch-Dohmen R
Mol Ther Nucleic Acids. 2017 Jun 16.
PMID: 28624211 [PubMed - in process]
2. Nanomagnetic activation as a way to control the efficacy of nucleic Acid delivery.
Grześkowiak BF, Sánchez-Antequera Y, Hammerschmid E, Döblinger M, Eberbeck D, Woźniak A, Słomski R, Plank C, Mykhaylyk O
Pharm Res. 2015 Jan .
PMID: 25033763 [PubMed - in process]
3. Magnetic nanoparticle and magnetic field assisted siRNA delivery in vitro.
Mykhaylyk O, Sanchez-Antequera Y, Vlaskou D, Cerda MB, Bokharaei M, Hammerschmid E, Anton M, Plank C
Methods Mol Biol. 2015 .
PMID: 25319646 [PubMed - in process]
4. Magnetic and acoustically active microbubbles loaded with nucleic acids for gene delivery.
Vlaskou D, Plank C, Mykhaylyk O
Methods Mol Biol. 2013 .
PMID: 23070773 [PubMed - in process]
5. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields.
Plank C, Scherer F, Schillinger U, Bergemann C, Anton M
J Liposome Res. 2003 Feb .
PMID: 12725725 [PubMed - in process]
6. A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses.
Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G, Coester C, Gehlen H
Pharm Res. 2012 Jun .
PMID: 22302522 [PubMed - in process]
7. The use of non-viral gene vectors for bioactive poly-(D,L-lactide) implant surfaces in bone tissue engineering.
Reckhenrich AK, Koch C, Egaña JT, Plank C
Eur Cell Mater. 2012 .
PMID: 22736203
8. Optimizing adenoviral transduction of endothelial cells under flow conditions.
Anton M, Wolf A, Mykhaylyk O, Koch C, Gansbacher B, Plank C
Pharm Res. 2012 May .
PMID: 22207207 [PubMed - in process]
9. Silica-iron oxide magnetic nanoparticles modified for gene delivery: a search for optimum and quantitative criteria.
Mykhaylyk O, Sobisch T, Almstätter I, Sanchez-Antequera Y, Brandt S, Anton M, Döblinger M, Eberbeck D, Settles M, Braren R, Lerche D, Plank C
Pharm Res. 2012 May .
PMID: 22222384 [PubMed - in process]
10. Site directed vascular gene delivery in vivo by ultrasonic destruction of magnetic nanoparticle coated microbubbles.
Mannell H, Pircher J, Fochler F, Stampnik Y, Räthel T, Gleich B, Plank C, Mykhaylyk O, Dahmani C, Wörnle M, Ribeiro A, Pohl U, Krötz F
Nanomedicine. 2012 Nov .
PMID: 22480917 [PubMed - in process]